US Pharma MarketingPfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation is a pharma and life sciences industry update from FierceBiotech. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Pfizer is paying Innovent $650 million upfront to partner on cancer drug development, following Bristol Myers Squibb by striking a broad pact that positions it to leverage China’s fast early development system.
Source: FierceBiotech